Patents by Inventor Merav Darash Yahana

Merav Darash Yahana has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NAF-1 derived peptides and uses thereof
    Patent number: 11208443
    Abstract: The present invention provides peptides comprising a sequence derived from the human NAF-1 protein, analogs of said sequence or a retro-inverso sequence of said peptide or analog. The conjugates of such peptides are provided as well. The peptides and the conjugates of the present invention are useful in treating cancer, and in particular cancer in which the expression of NAF-1 is enhanced.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: December 28, 2021
    Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Rachel Nechushtai, Assaf Friedler, Anat Iosub-Amir, Merav Darash-Yahana, Yang-Sung Sohn, Dorit Michaeli
  • Allogeneic tumor cell vaccination
    Patent number: 10064927
    Abstract: The present invention relates to cancer immunotherapy, specifically to allogeneic tumor cell vaccines. According to some embodiments, the invention provides novel cell lines useful as therapeutic cell vaccine compositions. The invention further provides advantageous screening methods and means for identifying patients amenable for treatment with partially Human Leukocyte Antigen (HLA) matched allogeneic cell vaccines. Therapeutic compositions and methods for use in proliferative disorders are further provided.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: September 4, 2018
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Tamar Peretz, Michal Lotem, Arthur Machlenkin, Shoshana Frankenburg, Inna Ben David, Anna Kuznetz, Yael Gelfand, Galit Eisenberg, Merav Darash Yahana
  • ALLOGENEIC TUMOR CELL VACCINATION
    Publication number: 20160175416
    Abstract: The present invention relates to cancer immunotherapy, specifically to allogeneic tumor cell vaccines. According to some embodiments, the invention provides novel cell lines useful as therapeutic cell vaccine compositions. The invention further provides advantageous screening methods and means for identifying patients amenable for treatment with partially Human Leukocyte Antigen (HLA) matched allogeneic cell vaccines. Therapeutic compositions and methods for use in proliferative disorders are further provided.
    Type: Application
    Filed: February 23, 2016
    Publication date: June 23, 2016
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventors: Tamar PERETZ, Michal LOTEM, Arthur MACHLENKIN, Shoshana FRANKENBURG, Inna BEN DAVID, Anna KUZNETZ, Yael GELFAND, Galit EISENBERG, Merav DARASH YAHANA
  • Allogeneic tumor cell vaccination
    Patent number: 9301998
    Abstract: The present invention relates to cancer immunotherapy, specifically to allogeneic tumor cell vaccines. According to some embodiments, the invention provides novel cell lines useful as therapeutic cell vaccine compositions. The invention further provides advantageous screening methods and means for identifying patients amenable for treatment with partially Human Leukocyte Antigen (HLA) matched allogeneic cell vaccines. Therapeutic compositions and methods for use in proliferative disorders are further provided.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: April 5, 2016
    Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Tamar Peretz, Michal Lotem, Arthur Machlenkin, Shoshana Frankenburg, Inna Ben David, Anna Kuznetz, Yael Gelfand, Galit Eisenberg, Merav Darash Yahana
  • Allogeneic Tumor Cell Vaccination
    Publication number: 20140141045
    Abstract: The present invention relates to cancer immunotherapy, specifically to allogeneic tumor cell vaccines. According to some embodiments, the invention provides novel cell lines useful as therapeutic cell vaccine compositions. The invention further provides advantageous screening methods and means for identifying patients amenable for treatment with partially Human Leukocyte Antigen (HLA) matched allogeneic cell vaccines. Therapeutic compositions and methods for use in proliferative disorders are further provided.
    Type: Application
    Filed: November 15, 2013
    Publication date: May 22, 2014
    Inventors: Tamar Peretz, Michal Lotem, Arthur Machlenkin, Shoshana Frankenburg, Inna Ben David, Anna Kuznetz, Yael Gelfand, Galit Eisenberg, Merav Darash Yahana